The purpose of this study is to evaluate the 8-hour moisturization efficacy of OTC sunscreen lip balm after a single treatment application.

A single-center, randomized, controlled, intra-individual comparison, open label clinical study to determine the 8-hour moisturization efficacy of a sunscreen lip balm. Skin hydration will be assessed before (Baseline) and after (2, 4, 6 and 8 hours post-treatment) a single treatment with test product, compared to 'no treatment' as control, using a corneometer. Study treatments will be randomly assigned to 2 test sites delineated on the skin of the participant's volar forearms (one test site on each arm). A 1-week conditioning phase will precede the test day, during which participants will use the soap provided for personal washing.

Inclusion Criteria:

• Participant must provide a signed and dated, legally effective, informed consent document, which indicates they have been informed of, and understand, all pertinent aspects of the study, before any study procedures are performed (in conformance with 21 Code of Federal Regulations [CFR] Part 50: 'Protection of Human Subjects.')
• Participant must provide relevant details of their medical history and current/recent medications and treatments.
• Participant has completed a Health Insurance Portability and Accountability Act (HIPAA) Authorization Form in conformance with 45 CFR Parts 160 and 164.
• Participant must have completed a Photo Release Form.
• Participant must be able to read, write, speak and understand English.
• Participant must be in good general health.
• Participant must have a valid form of personal identification (photo identity [ID], driver's license, passport, permanent resident card, military ID card; forms cannot be expired)
• Male and female participants of child-bearing potential must agree to use a highly effective method of contraception for the duration of the study and for 14 days after treatment application. (Note: A participant is considered to be of child-bearing potential if, in the opinion of the Principle investigator [PI], they are biologically capable of having children and sexually active.
• Participant must agree to be sequestered in a temperature/humidity monitored test room at the clinical site (temperature 21 degree Celsius [C] +/- 2 degree C, relative humidity [RH] 50 percent [%] +/- 10%) for the duration of the test day (Visit 2), approximately 9.5 hours.
• Participant must agree to bring their own food (dry) and beverages to be consumed on the test day (Visit 2).
• Participant must agree not to consume hot or very cold food/beverages on the test day (Visit 2).
• Participant must agree to use the non-moisturizing soap provided for all personal washing during the conditioning phase of the study.
• Participant must agree to wear loose clothing for ease of access to the test sites (arms) and/or sleeves that can be easily rolled up.
• Participant must agree not to introduce any new cosmetic/toiletry products into their personal care regimen during the study.
• Participant must agree to refrain from any physical effort which might result in thermal regulation by sweating (for example, exercise class, rapid climbing of flights of stairs, jogging, cycling, brisk walking) for at least 2 hours prior to arriving the test day (Visit 2).
• Participant must agree to refrain from prolonged or excessive ultraviolet (UV) exposure (for example, sunbathing, tanning beds) for the duration of the study.
• Participant should be dependable and able to follow directions as outlined in the protocol and Informed Consent Form (ICF).

Exclusion Criteria:

• Participant with scheduled or planned Covid-19 vaccination during likely dates of study participation.
• Female participant who is pregnant, planning to become pregnant during the study, or breastfeeding ( self-reported).
• Participant with a history of sensitivity to any ingredient of the test material or skin marker pen, or latex; or any known sensitivities/allergies, including but not limited to cosmetic/toiletry products and topically applied skin treatment products/drugs.
• Participant with a history of an acute or chronic dermatologic, medical and/or physical condition that would, in the opinion of the investigator, confound study outcomes or increase the risk associated with participation. (Note: dry skin is not an exclusion per se; however, a participant with a level of dryness on the skin of the volar forearms that would, in the opinion of the investigator, confound study outcomes or increase the risk associated with participation should be excluded.
• Participant with a history of skin cancer, or currently undergoing treatment for active cancer of any kind.
• Participant with diabetes.
• Participant with a planned medical treatment/vaccination (other than the Covid-19 vaccination) during the study that would, in the opinion of the investigator, confound study outcomes or increase the risk associated with participation.
• Participant with a planned hospitalization during the study.
• Participant who is currently using, or has used in the past week, any systemic or topical corticosteroid, non-steroid anti-inflammatory drug, antihistamine, sympathomimetic, and/or vasoconstrictor or any other medication that would, in the opinion of the investigator, confound study outcomes or increase the risk associated with participation.
• Participant who is unwilling to cease use of personal care products (for example, moisturizers, lotions, sunscreens, sunless tanners) and/or topical medications at the test sites for the duration of the study.
• Participant who has had extensive UV exposure within 3 weeks of Screening (Visit 1).
• Participant with visual signs of irritation, sunburn, rashes, scratches, burn marks, scarring at the test sites that would interfere with corneometry measurements.
• Participant with excessive hair at the test sites that would interfere with corneometry measurements.
• Participant who has participated in a study involving the arms as a test site, or any other type of clinical study, within three weeks of screening (Visit 1).
• Participant who is an employee/contractor or immediate family member of the PI, study site or Sponsor.

IPD for this study will be made available via the Clinical Study Data Request site.

IPD will be made available within 6 months of publishing the results of the primary endpoint and safety data of the study.

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Safety population: included all randomized participants who received study treatment.

From screening until 14 days after last administration of study product (or last study procedure).

Adverse events (AEs), and therefore all serious adverse events (SAEs), were to be collected from immediately after a participant provided written consent to participate in the trial until 14 days following the last administration of test material (or the last study procedure). All SAEs were to be reported within 24 hours of detection. AEs were to be classified by Intensity (mild, moderate, severe); Causality (probable, possible, unlikely); Seriousness (serious or non-serious).